Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

J P Maffrand1

  • 1Sanofi Recherche, Toulouse, France.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1992
PubMed
Summary

Direct thrombin inhibitors offer new ways to control thrombosis and haemostasis. These novel drugs show promise in animal models, with clinical studies underway to assess patient benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Molecular pharmacology·2003
Same author

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Progress in brain research·2002
Same author

Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2002
Same author

Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.

Circulation·2001
Same author

A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.

Fundamental & clinical pharmacology·2001
Same author

Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2001

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombin is a key enzyme in thrombosis and hemostasis.
  • Thrombin also contributes to atherosclerosis, inflammation, and neurodegeneration.
  • Controlling thrombin activity is crucial for managing various pathological conditions.

Purpose of the Study:

  • To review the development of synthetic and recombinant direct thrombin inhibitors.
  • To discuss the mechanisms of action of these inhibitors.
  • To evaluate their potential advantages over existing treatments like heparin.

Main Methods:

  • Review of recent literature on direct thrombin inhibitors.
  • Analysis of inhibitor mechanisms targeting catalytic sites or exosites.
  • Examination of preclinical and clinical data from animal models and ongoing studies.

Main Results:

  • Numerous direct thrombin inhibitors have been developed.
  • Inhibitors target either the catalytic site, an anion-binding exosite, or both.
  • Some inhibitors demonstrate advantages over heparin in animal models of thrombosis and bleeding risk.

Conclusions:

  • Direct thrombin inhibitors represent a significant advancement in anticoagulation therapy.
  • Their ability to selectively inhibit thrombin offers therapeutic potential.
  • Ongoing clinical trials are essential to confirm their efficacy and safety in patients.

Related Experiment Videos